Your browser doesn't support javascript.
loading
First-in-human, phase I study of AK109, an anti-VEGFR2 antibody in patients with advanced or metastatic solid tumors.
Zheng, Y; Zhong, H; Zhao, F; Zhou, H; Mao, C; Lv, W; Yuan, M; Qian, J; Jiang, H; Wang, Z; Xiao, C; Guo, J; Liu, T; Liu, W; Wang, Z M; Li, B; Xia, M; Xu, N.
Affiliation
  • Zheng Y; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou.
  • Zhong H; The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou.
  • Zhao F; The First Affiliated Hospital, Bengbu Medical College, Bengbu.
  • Zhou H; The First Affiliated Hospital, Bengbu Medical College, Bengbu.
  • Mao C; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou.
  • Lv W; The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou.
  • Yuan M; The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou.
  • Qian J; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou.
  • Jiang H; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou.
  • Wang Z; The First Affiliated Hospital, Bengbu Medical College, Bengbu.
  • Xiao C; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou.
  • Guo J; Akeso Biopharma, Inc., Zhongshan, China.
  • Liu T; Akeso Biopharma, Inc., Zhongshan, China.
  • Liu W; Akeso Biopharma, Inc., Zhongshan, China.
  • Wang ZM; Akeso Biopharma, Inc., Zhongshan, China.
  • Li B; Akeso Biopharma, Inc., Zhongshan, China.
  • Xia M; Akeso Biopharma, Inc., Zhongshan, China.
  • Xu N; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou. Electronic address: nongxu@zju.edu.cn.
ESMO Open ; 8(2): 101156, 2023 04.
Article de En | MEDLINE | ID: mdl-36989884
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Récepteur-2 au facteur croissance endothéliale vasculaire / Tumeurs Type d'étude: Clinical_trials Limites: Humans Langue: En Journal: ESMO Open Année: 2023 Type de document: Article
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Récepteur-2 au facteur croissance endothéliale vasculaire / Tumeurs Type d'étude: Clinical_trials Limites: Humans Langue: En Journal: ESMO Open Année: 2023 Type de document: Article